These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 25802141)
1. Minimising menopausal side effects whilst treating endometriosis and fibroids. Simpson PD; McLaren JS; Rymer J; Morris EP Post Reprod Health; 2015 Mar; 21(1):16-23. PubMed ID: 25802141 [TBL] [Abstract][Full Text] [Related]
2. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show? Surrey ES Curr Opin Obstet Gynecol; 2010 Aug; 22(4):283-8. PubMed ID: 20498596 [TBL] [Abstract][Full Text] [Related]
3. An evidence-based approach to hormonal therapies for premenopausal women with fibroids. Lethaby AE; Vollenhoven BJ Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):307-31. PubMed ID: 17905660 [TBL] [Abstract][Full Text] [Related]
4. Oestrogen deficiency causes DNA damage in uterine leiomyoma cells: a possible mechanism for shrinkage of fibroids by GnRH agonists. Cheng YM; Chou CY; Huang SC; Lin HC BJOG; 2001 Jan; 108(1):95-102. PubMed ID: 11213012 [TBL] [Abstract][Full Text] [Related]
5. Gonadotrophin receptor hormone analogues in combination with add-back therapy: an update. McLaren JS; Morris E; Rymer J Menopause Int; 2012 Jun; 18(2):68-72. PubMed ID: 22611225 [TBL] [Abstract][Full Text] [Related]
7. The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis. Chwalisz K; Surrey E; Stanczyk FZ Reprod Sci; 2012 Jun; 19(6):563-71. PubMed ID: 22457429 [TBL] [Abstract][Full Text] [Related]
8. Serum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues. van der Spuy ZM; Wood M; Fieggen G; Hendricks MS S Afr Med J; 1993 Jul; 83(7):510-3. PubMed ID: 8211493 [TBL] [Abstract][Full Text] [Related]
9. An Evidence-based Approach to the Medical Management of Fibroids: A Systematic Review. Bartels CB; Cayton KC; Chuong FS; Holthouser K; Arian SE; Abraham T; Segars JH Clin Obstet Gynecol; 2016 Mar; 59(1):30-52. PubMed ID: 26756261 [TBL] [Abstract][Full Text] [Related]
10. Medical management of fibroids. Sankaran S; Manyonda IT Best Pract Res Clin Obstet Gynaecol; 2008 Aug; 22(4):655-76. PubMed ID: 18468953 [TBL] [Abstract][Full Text] [Related]
11. [GnRH analogues for the treatment of fibroids]. Murillo EO; Cano A Med Clin (Barc); 2013 Jul; 141 Suppl 1():35-9. PubMed ID: 24314566 [TBL] [Abstract][Full Text] [Related]
12. Long-term gonadotrophin-releasing hormone agonist therapy: the evolving issue of steroidal 'add-back' paradigms. Adashi EY Hum Reprod; 1994 Jul; 9(7):1380-97. PubMed ID: 7962453 [TBL] [Abstract][Full Text] [Related]
14. The levonorgestrel-releasing intrauterine system in modern gynaecology. McGavigan CJ; Owen P Br J Hosp Med (Lond); 2005 Oct; 66(10):574-7. PubMed ID: 16255257 [TBL] [Abstract][Full Text] [Related]
15. [Estrogen-progesterone "add-back" for long-term GNRH analogue therapy]. Levy T; Ben-Rafael Z Harefuah; 1995 Jun; 128(12):789-92. PubMed ID: 7557691 [No Abstract] [Full Text] [Related]
16. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Engel JB; Schally AV Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):157-67. PubMed ID: 17237842 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of tibolone as "add-back therapy" in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids. Morris EP; Rymer J; Robinson J; Fogelman I Fertil Steril; 2008 Feb; 89(2):421-8. PubMed ID: 17572410 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]